Gibson J R, Harvey S G, Barth J H, Moss M Y, Burke C A
Dermatologica. 1984;169(4):179-83. doi: 10.1159/000249599.
20 patients with a diagnosis of chronic idiopathic urticaria were entered into a double-blind placebo-controlled cross-over study. All patients completed the trial and during the assessment period they were treated with placebo, BW 825C (4 mg) and BW 825C (8 mg) according to a fully randomised and balanced treatment plan. Both doses of BW 825C were found to be highly effective and significantly better than placebo in controlling signs and symptoms of urticaria. Few adverse reactions were reported and in this small group of patients there was no significant difference from placebo in reports of drowsiness or any other side-effects.
20例诊断为慢性特发性荨麻疹的患者进入一项双盲、安慰剂对照的交叉研究。所有患者均完成了试验，在评估期间，根据完全随机且均衡的治疗方案，他们分别接受了安慰剂、BW 825C（4毫克）和BW 825C（8毫克）的治疗。结果发现，两种剂量的BW 825C在控制荨麻疹的体征和症状方面均非常有效，且显著优于安慰剂。报告的不良反应很少，在这一小群患者中，嗜睡或任何其他副作用的报告与安慰剂组相比无显著差异。
